Диссертация (1150007), страница 15
Текст из файла (страница 15)
Показано, что аналоги эстрогенов, содержащие фтор в положении 2 исвободную гидроксильную группу в положении 3, обладают высокой антиоксидантной активностью, сравнимой с антиоксидантсной активностью природного эстрадиола. На основе экспериментальных данных построена 3D-QSARмодель c хорошей предсказательной силой.109СПИСОК ЛИТЕРАТУРЫ1.Utne T., Jobson R.B., Babson R.D. Synthesis of 2-and 4-fluoroestradiol // J.
Org.Chem. – 1968. – Vol. 33. – № 6. – P. 2469–2473.2.Шавва А.Г., Селиванов С.И., Старова Г.Л., Бороноева Т.Р., Ищенко И.В.,Глуздиков И.А., Шарецкий А.Н., Исаева В.Г., Суринов Б.П. Cинтез иисследование ß-нop-8-изоаналогов стероидных эстрогенов // Биоорганическаяхимия – 2002.
– Vol. 28. – № 3. – P. 242–250.3.Wölfling J., Mernyák E., Frank É., Falkay G., Márki Á., Minorics R., Schneider G.Synthesis and receptor-binding examinations of the normal and 13- epi-Dhomoestrones and their 3-methyl ethers // Steroids – 2003. – Vol. 68. – № 3. – P.277–288.4.Roger V.L., Go A.S., Lloyd-Jones D.M., Benjamin E.J., Berry J.D., Borden W.B.,Bravata D.M., Dai S., Ford E.S., Fox C.S.
Executive Summary: Heart Disease andStroke Statistics—2012 Update A Report From the American Heart Association //Circulation – 2012. – Vol. 125. – № 1. – P. 188–197.5.Mendelsohn M.E., Karas R.H. Molecular and cellular basis of cardiovascular genderdifferences // Science (80-. ). – 2005. – Vol. 308. – № 5728.
– P. 1583–1587.6.Turgeon J.L., McDonnell D.P., Martin K.A., Wise P.M. Hormone therapy:physiological complexity belies therapeutic simplicity // Science (80-. ). – 2004. –Vol. 304. – № 5675. – P. 1269–1273.7.Deschamps A.M., Murphy E., Sun J. Estrogen receptor activation andcardioprotection in ischemia reperfusion injury // Trends Cardiovasc. Med. – 2010. –Vol. 20. – № 3. – P. 73–78.8.Jousilahti P., Vartiainen E., Tuomilehto J., Puska P. Sex, age, cardiovascular riskfactors, and coronary heart disease A prospective follow-up study of 14 786 middleaged men and women in Finland // Circulation – 1999. – Vol.
99. – № 9. – P. 1165–1172.9.Bush T.L., Barrett-Connor E., Cowan L.D., Criqui M.H., Wallace R.B., SuchindranC.M., Tyroler H.A., Rifkind B.M. Cardiovascular mortality and noncontraceptive useof estrogen in women: results from the Lipid Research Clinics Program Follow-upStudy. // Circulation – 1987. – Vol. 75. – № 6. – P. 1102–1109.10.Stocker R., Keaney J.F. Role of oxidative modifications in atherosclerosis // Physiol.Rev. – 2004. – Vol. 84. – № 4.
– P. 1381–1478.11.Bertoia M.L., Pai J.K., Lee J.-H., Taleb A., Joosten M.M., Mittleman M.A., Yang X.,Witztum J.L., Rimm E.B., Tsimikas S. Oxidation-specific biomarkers and risk ofperipheral artery disease // J. Am. Coll. Cardiol. – 2013. – Vol. 61. – № 21.
– P.2169–2179.11012.Lönn M.E., Dennis J.M., Stocker R. Actions of “antioxidants” in the protectionagainst atherosclerosis // Free Radic. Biol. Med. – 2012. – Vol. 53. – № 4. – P. 863–884.13.Vera-Ramirez L., Ramirez-Tortosa Mc., Perez-Lopez P., Granados-Principal S.,Battino M., Quiles J.L. Long-term effects of systemic cancer treatment on DNAoxidative damage: the potential for targeted therapies // Cancer Lett. – 2012. – Vol.327. – № 1. – P.
134–141.14.Prokai L., Simpkins J.W. Structure-nongenomic neuroprotection relationship ofestrogens and estrogen-derived compounds. // Pharmacol. Ther. – 2007. – Vol. 114. –№ 1. – P. 1–12.15.Steinberg D. The LDL modification hypothesis of atherogenesis: an update // J. LipidRes. – 2009. – Vol. 50. – № Supplement. – P. S376–S381.16.Prokai L., Prokai-Tatrai K., Perjesi P., Zharikova A.D., Perez E.J., Liu R., SimpkinsJ.W. Quinol-based cyclic antioxidant mechanism in estrogen neuroprotection // Proc.Natl.
Acad. Sci. – 2003. – Vol. 100. – № 20. – P. 11741–11746.17.Prokai L., Simpkins J.W. Structure–nongenomic neuroprotection relationship ofestrogens and estrogen-derived compounds // Pharmacol. Ther. – 2007. – Vol. 114. –№ 1. – P. 1–12.18.Abplanalp W., Scheiber M.D., Moon K., Kessel B., Liu J.H., Subbiah M.T. Evidencefor the role of high density lipoproteins in mediating the antioxidant effect ofestrogens // Eur. J. Endocrinol. – 2000.
– Vol. 142. – № 1. – P. 79–83.19.Subbiah M.T., Kessel B., Agrawal M., Rajan R., Abplanalp W., Rymaszewski Z.Antioxidant potential of specific estrogens on lipid peroxidation. // J. Clin.Endocrinol. Metab. – 1993. – Vol. 77. – № 4. – P. 1095–1097.20.Libby P. Inflammation in atherosclerosis. // Arterioscler. Thromb. Vasc. Biol. – 2012.– Vol. 32. – № 9. – P. 2045–2051.21.Prokai-Tatrai K., Perjesi P., Rivera-Portalatin N.M., Simpkins J.W., Prokai L.Mechanistic investigations on the antioxidant action of a neuroprotective estrogenderivative // Steroids – 2008. – Vol.
73. – № 3. – P. 280–288.22.Perrella J., Berco M., Cecutti A., Gerulath A., Bhavnani B.R. Potential role of theinteraction between equine estrogens, low-density lipoprotein (LDL) and high-densitylipoprotein (HDL) in the prevention of coronary heart and neurodegenerative diseasesin postmenopausal women // Lipids Health Dis. – 2003. – Vol. 2. – № 1. – P. 4.23.Droescher P., Menzenbach B., Roemer W., Schneider B., Elger W., Kaufmann G.Non-estrogenic estradiol derivative compounds with anti-oxidative activity //US6436917 – 2002.11124.Mazière C., Auclair M., Ronveaux M.-F., Salmon S., Santus R., Maziere J.-C.Estrogens inhibit copper and cell-mediated modification of low density lipoprotein //Atherosclerosis – 1991.
– Vol. 89. – № 2. – P. 175–182.25.Badeau M., Adlercreutz H., Kaihovaara P., Tikkanen M.J. Estrogen A-ring structureand antioxidative effect on lipoproteins // J. Steroid Biochem. Mol. Biol. – 2005. –Vol. 96. – № 3-4. – P. 271–278.26.Expert Panel on Detection E. Executive summary of the third report of the NationalCholesterol Education Program (NCEP) expert panel on Detection, Evaluation, andTreatment of high blood cholesterol in adults (Adult Treatment Panel III). // JAMA J.Am. Med. Assoc.
– 2001. – Vol. 285. – № 19. – P. 2486.27.Tall A.R. Cholesterol efflux pathways and other potential mechanisms involved in theathero‐protective effect of high density lipoproteins // J. Intern. Med. – 2008. – Vol.263. – № 3. – P. 256–273.28.Sacks F.M., Rudel L.L., Conner A., Akeefe H., Kostner G., Baki T., Rothblat G., dela Llera-Moya M., Asztalos B., Perlman T. Selective delipidation of plasma HDLenhances reverse cholesterol transport in vivo // J.
Lipid Res. – 2009. – Vol. 50. – №5. – P. 894–907.29.Shah P.K. The yin and yang of cholesteryl ester transfer protein in cardiovasculardisease // Circulation – 2009. – Vol. 120. – № 24. – P. 2408–2410.30.Hasselwander O., McEneny J., McMaster D., Fogarty D.G., Nicholls D.P., MaxwellA.P., Young I.S. HDL composition and HDL antioxidant capacity in patients onregular haemodialysis // Atherosclerosis – 1999. – Vol.
143. – № 1. – P. 125–133.31.Moradi H., Pahl M. V, Elahimehr R., Vaziri N.D. Impaired antioxidant activity ofhigh-density lipoprotein in chronic kidney disease // Transl. Res. – 2009. – Vol. 153.– № 2. – P. 77–85.32.Toth P.P., Maki K. Practical lipid management: concepts and controversies // JohnWiley Sons – 2008.33.Assmann G., Gotto A.M. HDL cholesterol and protective factors in atherosclerosis //Circulation – 2004. – Vol. 109. – № 23 suppl 1. – P.
III–8.34.Jones P.H., Davidson M.H., Stein E.A., Bays H.E., McKenney J.M., Miller E., CainV.A., Blasetto J.W. Comparison of the efficacy and safety of rosuvastatin versusatorvastatin, simvastatin, and pravastatin across doses // Am. J. Cardiol.
– 2003. –Vol. 92. – № 2. – P. 152–160.35.Nissen S.E., Nicholls S.J., Sipahi I., Libby P., Raichlen J.S., Ballantyne C.M.,Davignon J., Erbel R., Fruchart J.C., Tardif J.-C. Effect of very high-intensity statintherapy on regression of coronary atherosclerosis: the ASTEROID trial // Jama –2006. – Vol. 295. – № 13.
– P. 1556–1565.11236.Manninen V., Elo M.O., Frick M.H., Haapa K., Heinonen O.P., Heinsalmi P., Helo P.,Huttunen J.K., Kaitaniemi P., Koskinen P. Lipid alterations and decline in theincidence of coronary heart disease in the Helsinki Heart Study // Jama – 1988. – Vol.260. – № 5. – P. 641–651.37.Rubic T., Trottmann M., Lorenz R.L. Stimulation of CD36 and the key effector ofreverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin //Biochem.
Pharmacol. – 2004. – Vol. 67. – № 3. – P. 411–419.38.Toth P.P. Torcetrapib and atherosclerosis: what happened and where do we go fromhere? // Futur. Med. – 2007. – Vol. 2. – № 3. – P. 277–284.39.Tikkanen M.J., Nikkila E.A., Kuusi T., Sipinen S. High density lipoprotein-2 andhepatic lipase: Reciprocal changes produced by estrogen and Norgestrel // J. Clin.Endocrinol. Metab. – 1982. – Vol. 54. – № 6. – P. 1113–1117.40.Jin F.-Y., Kamanna V.S., Kashyap M.L.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
